EGFR TKI-treated NSCLC patients with the higher SGLT1-expressing tumors showed a lower overall survival rate with statistical significance (Fig. 5a) and a more unfavorable progression-free survival rate with marginal significance (Fig. 5b). This evidence concerns the gene EGFR and non-small cell lung carcinoma.